Pharmacological management of co-morbid conditions at the end of life: is less more?

Hdl Handle:
http://hdl.handle.net/10147/301991
Title:
Pharmacological management of co-morbid conditions at the end of life: is less more?
Authors:
McLean, S; Sheehy-Skeffington, B; O'Leary, N; O'Gorman, A
Affiliation:
Specialist Palliative Care Service, Dochas Centre, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland. smclean81@yahoo.com
Citation:
Pharmacological management of co-morbid conditions at the end of life: is less more? 2013, 182 (1):107-12 Ir J Med Sci
Journal:
Irish journal of medical science
Issue Date:
Mar-2013
URI:
http://hdl.handle.net/10147/301991
DOI:
10.1007/s11845-012-0841-6
PubMed ID:
22843427
Abstract:
Co-morbid conditions (CMCs) are present in over half of patients with cancer over 50 years of age. As life-limiting illnesses progress, the benefits and burdens of treatments for CMCs become unclear. Relevant issues include physiological changes in advanced illness, time-to-benefit of medications, burden of medications, and psychological impact of discontinuing medications. Optimal prescribing is unclear due to lack of evidence.
Item Type:
Article
Language:
en
MeSH:
Aged; Alzheimer Disease; Comorbidity; Female; Humans; Inappropriate Prescribing; Kidney Failure, Chronic; Male; Middle Aged; Neoplasms; Peripheral Vascular Diseases; Polypharmacy; Pulmonary Disease, Chronic Obstructive; Stroke; Terminal Care
ISSN:
1863-4362

Full metadata record

DC FieldValue Language
dc.contributor.authorMcLean, Sen_GB
dc.contributor.authorSheehy-Skeffington, Ben_GB
dc.contributor.authorO'Leary, Nen_GB
dc.contributor.authorO'Gorman, Aen_GB
dc.date.accessioned2013-09-20T08:07:13Z-
dc.date.available2013-09-20T08:07:13Z-
dc.date.issued2013-03-
dc.identifier.citationPharmacological management of co-morbid conditions at the end of life: is less more? 2013, 182 (1):107-12 Ir J Med Scien_GB
dc.identifier.issn1863-4362-
dc.identifier.pmid22843427-
dc.identifier.doi10.1007/s11845-012-0841-6-
dc.identifier.urihttp://hdl.handle.net/10147/301991-
dc.description.abstractCo-morbid conditions (CMCs) are present in over half of patients with cancer over 50 years of age. As life-limiting illnesses progress, the benefits and burdens of treatments for CMCs become unclear. Relevant issues include physiological changes in advanced illness, time-to-benefit of medications, burden of medications, and psychological impact of discontinuing medications. Optimal prescribing is unclear due to lack of evidence.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Irish journal of medical scienceen_GB
dc.subject.meshAged-
dc.subject.meshAlzheimer Disease-
dc.subject.meshComorbidity-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInappropriate Prescribing-
dc.subject.meshKidney Failure, Chronic-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshPeripheral Vascular Diseases-
dc.subject.meshPolypharmacy-
dc.subject.meshPulmonary Disease, Chronic Obstructive-
dc.subject.meshStroke-
dc.subject.meshTerminal Care-
dc.titlePharmacological management of co-morbid conditions at the end of life: is less more?en_GB
dc.typeArticleen
dc.contributor.departmentSpecialist Palliative Care Service, Dochas Centre, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland. smclean81@yahoo.comen_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.